Form 4: Denali CMO Sells Shares for Tax, 10b5-1 Plan

Denali Therapeutics' Chief Medical Officer, Carole Ho, sold shares to cover tax obligations and under a pre-arranged trading plan.

Summary

• Carole Ho, Chief Medical Officer of Denali Therapeutics Inc., reported sales of common stock.
• On August 12, 2025, 2,937 shares were sold at a weighted average price of $13.58 per share to satisfy tax obligations related to the settlement of previously vested restricted stock units.
• On August 13, 2025, an additional 806 shares were sold at $14.64 per share pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
• Following these transactions, direct beneficial ownership stands at 216,585 shares, which includes 128,405 unvested restricted stock units.
• Indirect beneficial ownership includes 183,219 shares held by the Rohatgi-Ho Family 2009 Revocable Trust and 25,000 shares held by The Rohatgi-Ho Irrevocable GST Trust.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales for tax obligations and a pre-arranged trading plan, which are common and generally neutral events that do not indicate a significant positive or negative sentiment towards the company's prospects.

Positives

• The sale on August 13, 2025, was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a discretionary sale based on new information.

Negatives

• Insider selling, even for tax purposes or pre-planned, reduces the insider's direct stake in the company.

Future Outlook

This filing is a Form 4, which reports insider transactions and does not typically contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. Sales for tax obligations related to equity compensation and sales under Rule 10b5-1 plans are common practices for corporate executives to manage their equity holdings and liquidity in a compliant manner.

Related Party Transactions

• The reporting person holds indirect beneficial ownership of 183,219 shares through the Rohatgi-Ho Family 2009 Revocable Trust, for which she serves as trustee.
• The reporting person holds indirect beneficial ownership of 25,000 shares through The Rohatgi-Ho Irrevocable GST Trust, which is for the benefit of her children.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, though the stated reasons (tax obligations and a pre-planned trading arrangement) are generally considered benign and routine for executives.

Key Dates

Keywords

Denali Therapeutics, DNLI, Carole Ho, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Restricted Stock Units, RSU